Exane BNP Paribas re-initiates Sonova with 'underperform'

Demant A/S

20/10/2025 11:35

** Exane BNP Paribas restarts its coverage on Sonova SOON.S with "underperform", citing concerns over the Swiss hearing aids maker's full-year guidance

** Among main headwinds, the brokerage notes weaker underlying end markets, high competition and market share erosion

** It prefers Sonova's Danish rival "outperform"-rated Demant DEMANT.CO, which it sees as benefiting from the upcoming launch of its next-generation product

** Despite the 27% share price fall so far this year, the broker says it sees room for additional downside

** Out of 17 analysts that cover Sonova, four rate the stock "strong buy" or "buy,"​ eight rate it "hold" and five​ rate "strong sell" or "sell" - LSEG data

 (Reporting by Amir Orusov)

 ((Amir.orusov@thomsonreuters.com))